SOPHiA GENETICS SA (SOPH) Bundle
An Overview of SOPHiA GENETICS SA (SOPH)
General Summary of SOPHiA GENETICS SA (SOPH)
SOPHiA GENETICS SA is a global healthcare technology company headquartered in Saint-Sulpice, Switzerland. The company specializes in data-driven precision medicine solutions, focusing on AI-powered genomic and molecular diagnostic technologies.
| Company Metrics | Details |
|---|---|
| Founded | 2011 |
| Headquarters | Saint-Sulpice, Switzerland |
| Stock Exchange Listing | NASDAQ (SOPH) |
| Total Employees | 298 (as of 2023) |
Product Portfolio
- SOPHiA DDM Platform for genomic and molecular data analysis
- Oncology diagnostic solutions
- Hereditary cancer testing
- Tumor profiling technologies
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $37.4 million |
| Gross Margin | 59.3% |
| Net Loss | $54.3 million |
| Cash and Cash Equivalents | $126.7 million |
Market Leadership
SOPHiA GENETICS is recognized as a pioneering AI-driven precision medicine technology company with presence in over 780 healthcare institutions across 57 countries.
- Market leadership in genomic data interpretation
- Over 300,000 patient samples analyzed annually
- Partnerships with leading academic and research institutions
Mission Statement of SOPHiA GENETICS SA (SOPH)
Mission Statement of SOPHiA GENETICS SA (SOPH)
SOPHiA GENETICS SA mission statement focuses on leveraging artificial intelligence and data-driven technologies to transform precision medicine and healthcare diagnostics.
Core Mission Components
| AI Technology Integration | Develop AI-powered diagnostic solutions for complex medical challenges |
| Data Sharing Platform | Collaborative global network with 1,200+ healthcare institutions |
| Precision Medicine Focus | Genomic and molecular diagnostic solutions across multiple disease areas |
Strategic Mission Objectives
- Deploy AI-driven genomic analysis platforms
- Expand global healthcare data collaboration
- Accelerate personalized treatment development
Performance Metrics
Key performance indicators for 2024:
| Annual Revenue | $51.4 million |
| Global Healthcare Institutions | 1,200+ |
| AI Diagnostic Platforms | 7 specialized platforms |
| Research & Development Investment | $22.6 million |
Technology Capabilities
Proprietary AI Technologies:
- SOPHiA DDM platform
- Genomic variant interpretation
- Machine learning diagnostic algorithms
Vision Statement of SOPHiA GENETICS SA (SOPH)
Vision Statement Components of SOPHiA GENETICS SA (SOPH)
Global Healthcare Transformation StrategySOPHiA GENETICS SA aims to leverage artificial intelligence in genomic data analysis with the following specific vision parameters:
| Vision Dimension | Quantitative Target |
|---|---|
| Global Healthcare Market Penetration | 1,800+ healthcare institutions worldwide |
| AI-Driven Genomic Diagnostic Coverage | 25+ clinical areas analyzed |
| Annual Data Processing Capacity | Over 1 petabyte of genomic data |
- Precision medicine development
- Machine learning algorithm enhancement
- Genomic data interpretation accuracy
SOPHiA GENETICS SA's vision includes:
| Performance Indicator | 2024 Target |
|---|---|
| Revenue Growth | 19.4% year-over-year |
| Research & Development Investment | $42.3 million |
| Patent Portfolio | 87 active genomic technology patents |
Core Values of SOPHiA GENETICS SA (SOPH)
Core Values of SOPHiA GENETICS SA (SOPH)
Innovation and Technological Leadership
SOPHiA GENETICS demonstrates commitment to innovation through significant R&D investments.
| R&D Expenditure 2023 | Percentage of Revenue |
|---|---|
| $51.7 million | 56.4% |
Data-Driven Healthcare Solutions
The company focuses on AI-powered genomic data analysis platforms.
- Over 1,300 healthcare institutions globally using SOPHiA platform
- More than 1 million patients' genomic data analyzed
- AI algorithms covering 20+ cancer types
Collaborative Scientific Approach
| Global Research Partnerships | Number of Collaborations |
|---|---|
| Academic Institutions | 78 |
| Research Hospitals | 52 |
Commitment to Precision Medicine
SOPHiA GENETICS focuses on advancing personalized healthcare technologies.
- Genomic testing accuracy rate: 99.3%
- Diagnostic turnaround time: 5-7 days
Ethical Data Management
Rigorous data privacy and security protocols implemented.
| Compliance Certifications | Status |
|---|---|
| GDPR Compliance | Fully Compliant |
| HIPAA Standards | Certified |
SOPHiA GENETICS SA (SOPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.